Skip to content

Tag Archives: phase

22nd Century Group Announces Initial Results of Smoking Cessation Trial : Results will help determine the optimal nicotine content for X-22

Monday, December 26, 2011

22nd Century Group, Inc. (OTCBB: XXII), a company focused on smoking cessation and tobacco harm reduction products, today announced X-22, a prescription smoking cessation aid in development consisting of very low nicotine (VLN) cigarettes, showed a reduction of smoking from baseline over the 6-week treatment period in the company’s Phase II-B clinical trial

Filed in Harm Reduction, tobacco | Also tagged , , , , , , , | Comments (0)

Nalmefene Completes Clinical Phase III Programme Submission Of The European Marketing Authorization Application (MAA) Is Expected By The End Of 2011

Saturday, June 18, 2011

H. Lundbeck A/S (Lundbeck) announced the completion of the final study (ESENSE2) in the phase III clinical programme for nalmefene in patients with alcohol dependence. In this multi-center, double-blind, placebo-controlled study, 718 individuals were randomized to receive oral administration of 20 mg of nalmefene or placebo on an as-needed basis for a total of 28 weeks of treatment…

Filed in Uncategorized | Also tagged , , , , , , , , , , , | Comments (0)

Data On VIVITROL(R), The New FDA-Approved Medication For Prevention Of Relapse To Opioid Dependence, Published In The Lancet

Thursday, April 28, 2011

Alkermes, Inc. (NASDAQ: ALKS) today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo…

Filed in Uncategorized | Also tagged , , , , , , , , , | Comments (0)

Study Results Showed Non-Addictive, Non-Narcotic, Once-Monthly VIVITROL Effective For Treating Opioid Dependence

Thursday, April 28, 2011

Alkermes, Inc. (NASDAQ: ALKS) has announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by /iThe Lancet.

Filed in Uncategorized | Also tagged , , , , , , , , | Comments (0)

Titan Reports Patient Enrollment In Phase III Study Of Probuphine® Is Ahead Of Schedule

Thursday, August 5, 2010

Titan Pharmaceuticals, Inc.

Filed in Uncategorized | Also tagged , , , , , , , , , , , , , | Comments (0)

Titan Initiates Confirmatory Phase 3 Study Of Probuphine(R) In The Treatment Of Opioid Addiction

Wednesday, March 31, 2010

Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction…

Filed in Uncategorized | Also tagged , , , , , , , , | Comments (0)

Omeros Announces National Institute On Drug Abuse’s Support For Phase 2 Clinical Study In Addiction Program

Friday, January 29, 2010

Omeros Corporation (Nasdaq: OMER) announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company’s Addiction program.

Filed in Uncategorized | Also tagged , , , , , , , , , , , , , | Comments (0)